{
    "info": {
        "nct_id": "NCT06457997",
        "official_title": "First-in-Human, Phase 1b Study of PHN-010, an Antibody Drug Conjugate, in Patients with Advanced Solid Tumors",
        "inclusion_criteria": "* Has histologically confirmed, advanced/metastatic:\n\n  1. Colorectal adenocarcinoma (CRC), or\n  2. Serous, endometroid, or clear-cell epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, or\n  3. Serous, endometroid or clear-cell endometrial cancer, or\n  4. Adenocarcinoma or squamous-cell carcinoma of the cervix, or\n  5. Non-small cell lung cancer (NSCLC).\n* Has received at least one prior systemic therapy and radiologically or clinically determined progressive disease during or after the most recent line of therapy, and for whom no further standard therapy is available or who is intolerant to standard therapy.\n* Has measurable disease.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Has adequate organ function.\n* Has available tumor tissue sample at screening (either an archival specimen collected ≤ 3 years prior to the date of informed consent or fresh biopsy material).\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Had prior treatment with any ADC containing topoisomerase-1 inhibiting payload.\n* Has unstable central nervous system metastasis.\n* Has persistent toxicities from previous systemic anti-cancer treatments of Grade >1.\n* Has received systemic anti-neoplastic therapy within five half-lives or 21 days, whichever is shorter, prior to first dose of the study drug.\n* Has received wide-field radiotherapy (> 30% of marrow-bearing bones) within 28 days, or focal radiation for analgesic purpose or for lytic lesions at risk of fracture within 14 days prior to first dose of the study drug, or no recovery from side effects of such intervention.\n* Had major surgery (not including placement of vascular access device or tumor biopsies) within 28 days prior to first dose of the study drug, or no recovery from side effects of such intervention.\n* Has acute and/or clinically significant bacterial, fungal, or viral infection including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV).\n* Has a history of non-infectious pneumonitis (NIP) / interstitial lung disease (ILD) requiring systemic steroids, active NIP / ILD or suspected NIP / ILD which cannot be ruled out by imaging for Screening.\n\nOther protocol defined Inclusion/Exclusion criteria apply.",
        "miscellaneous_criteria": "Key"
    },
    "inclusion_lines": [
        {
            "line": "* Has adequate organ function.",
            "criterions": [
                {
                    "exact_snippets": "Has adequate organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Colorectal adenocarcinoma (CRC), or",
            "criterions": [
                {
                    "exact_snippets": "Colorectal adenocarcinoma (CRC)",
                    "criterion": "colorectal adenocarcinoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Serous, endometroid, or clear-cell epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, or",
            "criterions": [
                {
                    "exact_snippets": "Serous, endometroid, or clear-cell epithelial ovarian cancer",
                    "criterion": "epithelial ovarian cancer",
                    "requirements": [
                        {
                            "requirement_type": "histology subtype",
                            "expected_value": [
                                "serous",
                                "endometroid",
                                "clear-cell"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "fallopian tube cancer",
                    "criterion": "fallopian tube cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "primary peritoneal cancer",
                    "criterion": "primary peritoneal cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has available tumor tissue sample at screening (either an archival specimen collected ≤ 3 years prior to the date of informed consent or fresh biopsy material).",
            "criterions": [
                {
                    "exact_snippets": "Has available tumor tissue sample at screening",
                    "criterion": "tumor tissue sample",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at screening"
                        }
                    ]
                },
                {
                    "exact_snippets": "archival specimen collected ≤ 3 years prior to the date of informed consent",
                    "criterion": "archival tumor tissue specimen",
                    "requirements": [
                        {
                            "requirement_type": "collection_time_before_consent",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "fresh biopsy material",
                    "criterion": "fresh biopsy material",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has histologically confirmed, advanced/metastatic:",
            "criterions": [
                {
                    "exact_snippets": "histologically confirmed",
                    "criterion": "diagnosis confirmation method",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": "histology"
                        }
                    ]
                },
                {
                    "exact_snippets": "advanced/metastatic",
                    "criterion": "disease stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "advanced",
                                "metastatic"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Non-small cell lung cancer (NSCLC).",
            "criterions": [
                {
                    "exact_snippets": "Non-small cell lung cancer (NSCLC)",
                    "criterion": "non-small cell lung cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has measurable disease.",
            "criterions": [
                {
                    "exact_snippets": "Has measurable disease.",
                    "criterion": "disease",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Serous, endometroid or clear-cell endometrial cancer, or",
            "criterions": [
                {
                    "exact_snippets": "Serous, endometroid or clear-cell endometrial cancer",
                    "criterion": "histological subtype of endometrial cancer",
                    "requirements": [
                        {
                            "requirement_type": "subtype",
                            "expected_value": [
                                "serous",
                                "endometroid",
                                "clear-cell"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has received at least one prior systemic therapy and radiologically or clinically determined progressive disease during or after the most recent line of therapy, and for whom no further standard therapy is available or who is intolerant to standard therapy.",
            "criterions": [
                {
                    "exact_snippets": "Has received at least one prior systemic therapy",
                    "criterion": "prior systemic therapy",
                    "requirements": [
                        {
                            "requirement_type": "number of prior systemic therapies",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "radiologically or clinically determined progressive disease during or after the most recent line of therapy",
                    "criterion": "progressive disease",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": "during or after the most recent line of therapy"
                        },
                        {
                            "requirement_type": "determination method",
                            "expected_value": [
                                "radiologically",
                                "clinically"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "for whom no further standard therapy is available",
                    "criterion": "availability of further standard therapy",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "who is intolerant to standard therapy",
                    "criterion": "tolerance to standard therapy",
                    "requirements": [
                        {
                            "requirement_type": "tolerance",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Adenocarcinoma or squamous-cell carcinoma of the cervix, or",
            "criterions": [
                {
                    "exact_snippets": "Adenocarcinoma ... of the cervix",
                    "criterion": "adenocarcinoma of the cervix",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "squamous-cell carcinoma of the cervix",
                    "criterion": "squamous-cell carcinoma of the cervix",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Had prior treatment with any ADC containing topoisomerase-1 inhibiting payload.",
            "criterions": [
                {
                    "exact_snippets": "Had prior treatment with any ADC containing topoisomerase-1 inhibiting payload",
                    "criterion": "prior treatment with ADC containing topoisomerase-1 inhibiting payload",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has persistent toxicities from previous systemic anti-cancer treatments of Grade >1.",
            "criterions": [
                {
                    "exact_snippets": "persistent toxicities from previous systemic anti-cancer treatments of Grade >1",
                    "criterion": "toxicities from previous systemic anti-cancer treatments",
                    "requirements": [
                        {
                            "requirement_type": "persistence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "grade",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Had major surgery (not including placement of vascular access device or tumor biopsies) within 28 days prior to first dose of the study drug, or no recovery from side effects of such intervention.",
            "criterions": [
                {
                    "exact_snippets": "Had major surgery (not including placement of vascular access device or tumor biopsies) within 28 days prior to first dose of the study drug",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "no recovery from side effects of such intervention",
                    "criterion": "recovery from side effects of major surgery",
                    "requirements": [
                        {
                            "requirement_type": "recovery status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has unstable central nervous system metastasis.",
            "criterions": [
                {
                    "exact_snippets": "unstable central nervous system metastasis",
                    "criterion": "central nervous system metastasis",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has acute and/or clinically significant bacterial, fungal, or viral infection including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV).",
            "criterions": [
                {
                    "exact_snippets": "Has acute and/or clinically significant bacterial, fungal, or viral infection",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "bacterial",
                                "fungal",
                                "viral"
                            ]
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "acute and/or clinically significant"
                        }
                    ]
                },
                {
                    "exact_snippets": "including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV)",
                    "criterion": "specific viral infections",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "hepatitis B (HBV)",
                                "hepatitis C (HCV)",
                                "human immunodeficiency virus (HIV)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has received systemic anti-neoplastic therapy within five half-lives or 21 days, whichever is shorter, prior to first dose of the study drug.",
            "criterions": [
                {
                    "exact_snippets": "Has received systemic anti-neoplastic therapy within five half-lives or 21 days, whichever is shorter, prior to first dose of the study drug.",
                    "criterion": "systemic anti-neoplastic therapy",
                    "requirements": [
                        {
                            "requirement_type": "recency of administration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 21,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has received wide-field radiotherapy (> 30% of marrow-bearing bones) within 28 days, or focal radiation for analgesic purpose or for lytic lesions at risk of fracture within 14 days prior to first dose of the study drug, or no recovery from side effects of such intervention.",
            "criterions": [
                {
                    "exact_snippets": "Has received wide-field radiotherapy (> 30% of marrow-bearing bones) within 28 days",
                    "criterion": "wide-field radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "treatment_received",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment_extent",
                            "expected_value": {
                                "operator": ">",
                                "value": 30,
                                "unit": "% of marrow-bearing bones"
                            }
                        },
                        {
                            "requirement_type": "treatment_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to first dose"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "focal radiation for analgesic purpose or for lytic lesions at risk of fracture within 14 days prior to first dose of the study drug",
                    "criterion": "focal radiation",
                    "requirements": [
                        {
                            "requirement_type": "treatment_received",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment_indication",
                            "expected_value": [
                                "analgesic purpose",
                                "lytic lesions at risk of fracture"
                            ]
                        },
                        {
                            "requirement_type": "treatment_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to first dose"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "no recovery from side effects of such intervention",
                    "criterion": "recovery from side effects of radiotherapy or focal radiation",
                    "requirements": [
                        {
                            "requirement_type": "recovery_status",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "Other protocol defined Inclusion/Exclusion criteria apply.",
            "criterions": [
                {
                    "exact_snippets": "Other protocol defined Inclusion/Exclusion criteria apply.",
                    "criterion": "other protocol defined inclusion/exclusion criteria",
                    "requirements": [
                        {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a history of non-infectious pneumonitis (NIP) / interstitial lung disease (ILD) requiring systemic steroids, active NIP / ILD or suspected NIP / ILD which cannot be ruled out by imaging for Screening.",
            "criterions": [
                {
                    "exact_snippets": "history of non-infectious pneumonitis (NIP) / interstitial lung disease (ILD) requiring systemic steroids",
                    "criterion": "non-infectious pneumonitis (NIP) or interstitial lung disease (ILD)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "requiring systemic steroids"
                        }
                    ]
                },
                {
                    "exact_snippets": "active NIP / ILD",
                    "criterion": "non-infectious pneumonitis (NIP) or interstitial lung disease (ILD)",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "suspected NIP / ILD which cannot be ruled out by imaging for Screening",
                    "criterion": "non-infectious pneumonitis (NIP) or interstitial lung disease (ILD)",
                    "requirements": [
                        {
                            "requirement_type": "suspected diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "confirmation by imaging",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [
        {
            "line": "Key",
            "criterions": [
                {
                    "exact_snippets": "Key",
                    "criterion": "key status",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": "key"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}